Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma

NACompletedINTERVENTIONAL
Enrollment

314

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

March 31, 2006

Study Completion Date

October 31, 2009

Conditions
Melanoma (Skin)
Interventions
GENETIC

comparative genomic hybridization

GENETIC

cytogenetic analysis

GENETIC

fluorescence in situ hybridization

OTHER

immunohistochemistry staining method

Trial Locations (27)

10021

Memorial Sloan-Kettering Cancer Center, New York

12801

Charles R. Wood Cancer Center at Glens Falls Hospital, Glens Falls

13057

CCOP - Hematology-Oncology Associates of Central New York, Syracuse

13215

Community General Hospital of Greater Syracuse, Syracuse

24541

Danville Regional Medical Center, Danville

27534

Wayne Memorial Hospital, Incorporated, Goldsboro

Wayne Radiation Oncology, Goldsboro

29401

Roper St. Francis Cancer Center at Roper Hospital, Charleston

52402

Iowa Blood and Cancer Care, Cedar Rapids

St. Luke's Hospital, Cedar Rapids

52403

Mercy Regional Cancer Center at Mercy Medical Center, Cedar Rapids

55455

Fairview University Medical Center - University Campus, Minneapolis

65101

Capital Region Cancer Center, Jefferson City

65203

Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia

60637-1470

University of Chicago Cancer Research Center, Chicago

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Brigham and Women's Hospital, Boston

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

01605

Commonwealth Hematology-Oncology P.C. - Worcester, Worcester

03431

Kingsbury Center for Cancer Care at Cheshire Medical Center, Keene

03756-0002

Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon

27893-3428

Wilson Medical Center, Wilson

27157-1096

Wake Forest University Comprehensive Cancer Center, Winston-Salem

02903

Rhode Island Hospital, Providence

02906

Miriam Hospital at Lifespan, Providence

05602

Mountainview Medical, Berlin Corners

05401

Fletcher Allen Health Care - University Health Center Campus, Burlington

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Alliance for Clinical Trials in Oncology

OTHER

NCT00049010 - Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma | Biotech Hunter | Biotech Hunter